Authors
Alexander Reuss, Andreas Du Bois, Philipp Harter, Christina Fotopoulou, Jalid Sehouli, Giovanni Aletti, Frederic Guyon, Stefano Greggi, Berit Jul Mosgaard, Alexander Reinthaller, Felix Hilpert, Carmen Schade-Brittinger, Dennis S Chi, Sven Mahner
Publication date
2019/10/1
Journal
International Journal of Gynecologic Cancer
Volume
29
Issue
8
Publisher
BMJ Specialist Journals
Description
Background
Primary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC‐GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection.
Primary Objective
To clarify the optimal timing of surgical therapy in advanced ovarian cancer.
Study Hypothesis
Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer.
Trial Design
TRUST is an international open, randomized, controlled multi-center trial investigating overall survival after primary cytoreductive surgery versus neoadjuvant …
Scholar articles
A Reuss, A Du Bois, P Harter, C Fotopoulou, J Sehouli… - International Journal of Gynecologic Cancer, 2019